According to a new report published by Introspective Market Research, Psoriatic Arthritis Treatment Market by Drug Class (Biologics, DMARDs, NSAIDs, Others), Route of Administration (Oral, Injectable, Topical), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), The Global Psoriatic Arthritis Treatment Market Size Was Valued at USD 11.4 Billion in 2023 and is Projected to Reach USD 22.4 Billion by 2032, Growing at a CAGR of 7.8%.

Introduction / Market Overview:

The global psoriatic arthritis (PsA) treatment market is a critical pillar of the rheumatology and dermatology sectors, dedicated to managing a complex chronic inflammatory condition that affects both the joints and the skin. Psoriatic arthritis occurs in approximately 30% of individuals with psoriasis, leading to joint pain, stiffness, and potential permanent joint damage if left untreated. Modern treatment regimens have shifted significantly from basic symptom management to targeted systemic therapies. These advanced solutions offer substantial advantages over traditional options by slowing disease progression, improving physical function, and achieving high rates of skin clearance simultaneously.

In the current medical landscape, the market is characterized by a rapid transition toward precision medicine. Innovations such as Interleukin (IL) inhibitors and Janus kinase (JAK) inhibitors have redefined the standard of care, providing highly specific alternatives to conventional immunosuppressants. These therapies are utilized primarily across specialized rheumatology clinics and hospitals to treat moderate-to-severe cases where traditional non-steroidal anti-inflammatory drugs (NSAIDs) fail. As patient awareness grows and diagnostic tools become more sophisticated, the market continues to expand, driven by the need for multidisciplinary care that addresses the holistic burden of the disease.

Market Segmentation:

The Psoriatic Arthritis Treatment Market is segmented into Drug Class, Route of Administration, and Distribution Channel. By Drug Class, the market is categorized into (Biologics, Disease-modifying Anti-rheumatic Drugs (DMARDs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), and Others). By Route of Administration, the market is categorized into (Oral, Injectable, and Topical). By Distribution Channel, the market is categorized into (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies).

Growth Driver:

The primary driver for the Psoriatic Arthritis Treatment Market is the increasing global prevalence of psoriasis and the subsequent rise in PsA diagnosis rates. As sedentary lifestyles and environmental stressors contribute to a higher incidence of autoimmune disorders, a larger patient pool is seeking medical intervention. Furthermore, the development and approval of targeted biologic therapies and biosimilars have expanded treatment access. The entry of lower-cost biosimilars into the market has made advanced therapies more affordable for a broader population, particularly in emerging economies, thereby significantly boosting the volume of prescriptions and long-term market valuation.

Market Opportunity:

A significant market opportunity lies in the development of orally administered small-molecule inhibitors and personalized therapeutic regimens. While injectable biologics have long dominated the field, there is a growing patient preference for oral medications that offer comparable efficacy with greater convenience. The emergence of TYK2 inhibitors and next-generation JAK inhibitors represents a major shift toward oral systemic therapy. Additionally, the integration of digital health tools for remote patient monitoring allows clinicians to adjust treatments in real-time based on disease activity scores, opening a new avenue for pharmaceutical companies to offer integrated "drug-plus-service" packages.

Detailed Segmentation:

Title: Psoriatic Arthritis Treatment Market, Segmentation The Psoriatic Arthritis Treatment Market is segmented on the basis of Drug Class, Route of Administration, and Distribution Channel.

Drug Class The Drug Class segment is further classified into Biologics, DMARDs, and NSAIDs. Among these, the Biologics sub-segment accounted for the highest market share in 2023. This dominance is attributed to the high clinical efficacy of TNF-alpha inhibitors and Interleukin inhibitors (IL-17, IL-23) in preventing structural joint damage. Biologics are currently considered the gold standard for moderate-to-severe psoriatic arthritis due to their targeted mechanism of action, which offers superior outcomes in both skin clearance and joint health compared to traditional systemic therapies, securing the majority of revenue despite their higher cost.

Distribution Channel The Distribution Channel segment is further classified into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Among these, the Hospital Pharmacies sub-segment accounted for the highest market share in 2023. Hospital pharmacies are the primary points of access for specialized biologic treatments that often require professional administration via infusion or initial subcutaneous injection training. Furthermore, the complex nature of PsA often requires integrated hospital care, making these pharmacies the preferred choice for patients covered by comprehensive insurance plans that require strictly monitored pharmaceutical dispensing.

Some of The Leading/Active Market Players Are-

• AbbVie Inc. (USA)
• Amgen Inc. (USA)
• Johnson & Johnson Services, Inc. (USA)
• Novartis AG (Switzerland)
• Eli Lilly and Company (USA)
• Bristol Myers Squibb (USA)
• Pfizer Inc. (USA)
• UCB S.A. (Belgium)
• Merck & Co., Inc. (USA)
• Takeda Pharmaceutical Company Limited (Japan)
• Biogen Inc. (USA)
• Gilead Sciences, Inc. (USA)
• Sun Pharmaceutical Industries Ltd. (India)
• Celgene Corporation (USA)
• Sanofi (France)

and other active players.

Key Industry Developments

News 1: In June 2025, Bristol Myers Squibb reported positive results from its Phase 3 POETYK PsA-1 trial, which evaluated Sotyktu (deucravacitinib) in adults with active psoriatic arthritis. The study demonstrated that a significant percentage of patients achieved a 20% improvement in signs and symptoms (ACR20) compared to the placebo group. This development marks a major step forward for oral TYK2 inhibitors, potentially shifting the treatment paradigm away from injectables toward once-daily oral tablets for patients seeking effective and convenient options.

News 2: In April 2024, Alvotech and Teva Pharmaceuticals announced that their biosimilar, Selarsdi, received FDA approval as a biosimilar to Stelara for the treatment of psoriatic arthritis. This approval is expected to increase market competition and lower the cost of interleukin-12/23 inhibitor therapies. By providing a more affordable alternative to the reference biologic, Selarsdi helps expand patient access to critical treatments, particularly for those in healthcare systems with high out-of-pocket costs, thereby driving higher volume growth in the biologic segment.

Key Findings of the Study

• Dominant Segments: Biologics remain the leading drug class, while the injectable route of administration holds the majority share due to the prevalence of biologic agents.
• Leading Regions: North America dominates the market, but the Asia-Pacific region is projected to be the fastest-growing market through 2032.
• Key Growth Drivers: Rising prevalence of autoimmune skin conditions and the expansion of biosimilar availability.
• Market Trends: A notable shift toward oral small molecules and the increasing use of dual IL-17A/F inhibitors for superior skin and joint results.